
Please try another search
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Yoram Drucker | 60 | 2022 | Co-Founder, VP of Strategic Development & Chairman |
Michael Belkin | 84 | - | Member of Scientific Advisory Board |
Gadi Riesenfeld | - | 2023 | Independent Director |
James A. Richardson | 80 | 2011 | Independent Director |
Gabriel Zeilig | - | - | Member of Scientific Advisory Board |
Lior Shaltiel | - | 2022 | CEO & Director |
Oded Orgil | 58 | 2022 | Director |
Nahshon Knoller | - | 2024 | Head of the neurosurgery department at Shiba & Member of Scientific Advisory Board |
Shulamit Levenberg | 62 | - | Co-Founder & Member of Scientific Advisory Board |
Teodoro Forcht Dagi | 76 | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review